Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 17/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11237247 | 0.80 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2MEN1GAAMAPT | |
| SCHEMBL13283266 | 0.76 | HTT (1.00) | RAB9ASMN1; SMN2MEN1GAAMAPT | |
| SCHEMBL29496542 | 0.76 | HTT (1.00) | RAB9ASMN1; SMN2MEN1GAAMAPT | |
| SCHEMBL31197281 | 0.76 | HTT (1.00) | RAB9ASMN1; SMN2MEN1GAAMAPT | |
| SCHEMBL22097291 | 0.75 | HTT (0.72) | RAB9ASMN1; SMN2MEN1GAAMAPT | |
| SCHEMBL6836414 | 0.75 | EGFR (1.00) | RAB9ASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL30708444 | 0.74 | EGFR (0.56) | EGFR | |
| SCHEMBL30772876 | 0.70 | DYRK1A (0.56) | LMNAEGFR | |
| SCHEMBL6839115 | 0.69 | EGFR (0.70) | KDM4ELMNAHTTEGFR | |
| SCHEMBL30390568 | 0.69 | CD38 (0.54) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885369-B1 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8859545-B2 | Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases | EVOTEC AG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | RENOVIS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-7745451-B2 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | RENOVIS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | RAB9A 1986/4885SMN1; SMN2 1653/4885MEN1 4034/4885 |
| US-20100317676-A1 | Fused heterocyclic compounds, and compositions and uses thereof | OPRL1, OPRK1, IL1B | RAB9A 1064/4885SMN1; SMN2 1894/4885MEN1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.